重组人血管内皮抑素联合放疗在食管鳞癌中的应用

Application of Recombinant Human Endostatin Combined with Radiotherapy in Esophageal Squamous Cell Carcinoma

目的探讨重组人血管内皮抑素联合放疗治疗食管鳞癌的临床疗效。方法将110例食管鳞癌患者随机分为两组,每组55例。对照组采用放疗治疗,观察组在对照组基础上加用重组人血管内皮抑素治疗,比较两组治疗前后血清血管内皮生长因子(VEGF)的变化、临床疗效、1年生存率和局部控制率、生活质量(QOL)及不良反应。结果观察组有效率明显高于对照组,且疾病控制率有高于对照组的趋势;观察组和对照组1年生存率分别为68.5%和48.3%,1年局部控制率分别为60.3%和37.5%,两组比较差异均有统计学意义。观察组治疗后血清VEGF水平略低于对照组,但差异无统计学意义。观察组QOL改善情况及总有效率均明显高于对照组,而白细胞减少、血小板减少、恶心呕吐等不良反应的发生明显少于对照组。结论重组人血管内皮抑素联合放疗能明显改善食管鳞癌患者的QOL,临床疗效显著,且安全性好。

Objective To explore the clinical effect of recombinant human endostatin combined with radiotherapy in the treatment of esophageal squamous cell carcinoma. Methods One hundred and ten patients with esophageal squamous cell carcinoma were randomly divided into two groups, 55 cases in each group. The control group was treated with radiotherapy, while the observation group was added recombinant human endostatin based on control group. The changes of vascular endothelial growth factor（VEGF）before and after treatment, clinical effects, 1-year survival rate and local control rate,quality of life（QOL）and adverse reactions were compared in two groups. Results The response rate was obviously higher and disease control rate was slightly higher in observation group than in control group; 1-year survival rates and local control rates in observation group and control group were 68. 5 % and 60.3 %, 48. 3 % and 37.5%, respectively, with statistical significance. Serum VEGF levels after treatment were slightly lower in observation group than in control group, without statistical significance. QOL improvement and total response rate were markedly higher,while the adverse reactions like leukopenia, thrombocytopenia, nausea and vomiting were less in observation group than in control group. Conclusion Recombinant human endostatin combined with radiotherapy can effectively ameliorate QOL in patients with esophageal squamous cell carcinoma, with significant clinical effects and good safety.